Last reviewed · How we verify

NCT06730529

The Value of 68Ga-FAPI PET/CT in Preoperative Evaluation of Thyroid Cancer with Lymph Node Metastases

Recruiting now Last updated 12 December 2024
What this trial tests

trial in Thyroid Cancer in 40 participants. Currently enrolling.

Timeline
29 November 2024
Primary endpoint
31 December 2029
31 December 2029

Quick facts

Lead sponsorRuijin Hospital
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment40
Start date29 November 2024
Primary completion31 December 2029
Estimated completion31 December 2029
Sites1 location across China

Conditions studied

Sponsor

Ruijin Hospital

Who can join

Adults 16 to 80, any sex, with Thyroid Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to investigate the value of 68Ga-FAPI in the preoperative evaluation of thyroid cancer of different pathologic types.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Thyroid Cancer

Currently open trials in the same condition.

Other Ruijin Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06730529.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing